Wyeth
May 8, 2008
Biotech Stocks' Various Lupus Therapies: Opportunity or Lost Cause?
For a long time, few drugs were developed for rheumatological diseases. It was considered unattractive from a commercial viewpoint since relatively few patients suffered from them. via The Biotech Stock Blog
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

